Clinical performance of a prefabricated immunofluorescence assay for nasopharyngeal cancer screening

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Nasopharyngeal cancer (NPC) detection is crucial for improving patient survival.
• Epstein-Barr virus (EBV) IgA serology for viral capsid antigen (VCA) and early antigen (EA) is a key tool for early NPC diagnosis.
• Evaluating novel diagnostic tools for high-risk populations is essential.

Purpose of the Study:

• To assess the diagnostic performance of a prefabricated immunofluorescent assay (IFA) for Epstein-Barr virus (EBV) IgA serology in screening for nasopharyngeal cancer (NPC).
• To compare the efficacy of a new prefabricated IFA with traditional immunofluorescence methods for NPC detection.

Main Methods:

• Sera from 96 biopsy-proven NPC patients and 96 healthy controls were tested.
• Prevalent Epstein-Barr virus (EBV) viral capsid antigen (VCA) IgA and early antigen (EA) IgA were measured using a prefabricated EUROIMMUN (EI) IFA and a traditional IFA method.
• Diagnostic performance metrics, including Area Under the Curve (AUC), sensitivity, and specificity, were calculated.

Main Results:

• The prefabricated EI EBV-VCA IgA and EBV-EA IgA assays demonstrated high diagnostic accuracy with AUCs of 0.907 and 0.898, respectively.
• Combined testing using the prefabricated assay achieved 92.7% sensitivity and 81.2% specificity.
• The traditional EBV-EA IgA assay showed superior accuracy with 91.7% sensitivity and 96.9% specificity.

Conclusions:

• The prefabricated IFA test kit is a valuable tool for nasopharyngeal cancer (NPC) screening in high-risk populations.
• While the traditional immunofluorescence method offers higher accuracy, the prefabricated assay provides a practical alternative for screening.
• Further validation may be needed to optimize the prefabricated assay's performance for widespread clinical use.